EMT, CSCs, and Drug Resistance: the Mechanistic Link and Clinical Implications

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2017 Apr 12

PMID 28397828

Citations 1349

Authors

Tsukasa Shibue

Robert A Weinberg

Affiliations

Soon will be listed here.

Abstract

The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity - that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we summarize our current understanding of the link between the EMT programme and the CSC state, and also discuss how this knowledge can contribute to improvements in clinical practice.

Citing Articles

The Role of Epithelial-Mesenchymal Transition in Osteosarcoma Progression: From Biology to Therapy.

Patrascu A, Tarca E, Lozneanu L, Ungureanu C, Morosan E, Parteni D Diagnostics (Basel). 2025; 15(5).

PMID: 40075892 PMC: 11898898. DOI: 10.3390/diagnostics15050644.

Breast cancer: pathogenesis and treatments.

Xiong X, Zheng L, Ding Y, Chen Y, Cai Y, Wang L Signal Transduct Target Ther. 2025; 10(1):49.

PMID: 39966355 PMC: 11836418. DOI: 10.1038/s41392-024-02108-4.

Geniposide Inhibits Non-Small Cell Lung Cancer by Regulating Proliferation, Apoptosis, Invasion, Migration, Epithelial-Mesenchymal Transition, and Cancer Stem-Like Cell Property Via Wnt/β-Catenin Pathway.

He H, Li Y, Wang Y, Li M Biochem Genet. 2025; .

PMID: 39964646 DOI: 10.1007/s10528-025-11030-5.

CPT1A-mediated MFF succinylation promotes stemness maintenance in ovarian cancer stem cells.

Zhu Y, Chen S, Su H, Meng Y, Zang C, Ning P Commun Biol. 2025; 8(1):250.

PMID: 39956875 PMC: 11830779. DOI: 10.1038/s42003-025-07720-w.

A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling.

Ferrara Y, Latino D, Costagliola di Polidoro A, Oliver A, Sarnella A, Caprio M Cell Commun Signal. 2025; 23(1):74.

PMID: 39930439 PMC: 11809099. DOI: 10.1186/s12964-025-02073-7.

References

Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D . Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138(3):592-603. PMC: 2731699. DOI: 10.1016/j.cell.2009.07.011. View

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L . Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010; 70(17):6945-56. DOI: 10.1158/0008-5472.CAN-10-0785. View

Fischer K, Durrans A, Lee S, Sheng J, Li F, Wong S . Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015; 527(7579):472-6. PMC: 4662610. DOI: 10.1038/nature15748. View

Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T . Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol. 2003; 163(4):1437-47. PMC: 1868286. DOI: 10.1016/S0002-9440(10)63501-8. View

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9):744-9. DOI: 10.1038/nrc1694. View

Leung E, Fiscus R, Tung J, Tin V, Cheng L, Sihoe A . Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010; 5(11):e14062. PMC: 2988826. DOI: 10.1371/journal.pone.0014062. View

Ohlund D, Elyada E, Tuveson D . Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014; 211(8):1503-23. PMC: 4113948. DOI: 10.1084/jem.20140692. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

10.

Bouwens L, De Blay E . Islet morphogenesis and stem cell markers in rat pancreas. J Histochem Cytochem. 1996; 44(9):947-51. DOI: 10.1177/44.9.8773559. View

11.

Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

12.

Akhurst R, Hata A . Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012; 11(10):790-811. PMC: 3520610. DOI: 10.1038/nrd3810. View

13.

Tam W, Lu H, Buikhuisen J, Soh B, Lim E, Reinhardt F . Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013; 24(3):347-64. PMC: 4001722. DOI: 10.1016/j.ccr.2013.08.005. View

14.

Esteban M, Tran M, Harten S, Hill P, Castellanos M, Chandra A . Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006; 66(7):3567-75. DOI: 10.1158/0008-5472.CAN-05-2670. View

15.

Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

16.

Bjerkvig R, Tysnes B, Aboody K, Najbauer J, Terzis A . Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005; 5(11):899-904. DOI: 10.1038/nrc1740. View

17.

Chen Y, Chen Y, Hsu H, Tseng L, Huang P, Lu K . Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009; 385(3):307-13. DOI: 10.1016/j.bbrc.2009.05.048. View

18.

Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G . Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002-11. PMC: 3300837. DOI: 10.1186/bcr138. View

19.

Zavadil J, Bottinger E . TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24(37):5764-74. DOI: 10.1038/sj.onc.1208927. View

20.

Lee T, Poon R, Yuen A, Ling M, Kwok W, Wang X . Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006; 12(18):5369-76. DOI: 10.1158/1078-0432.CCR-05-2722. View